Abstract:Background and PurposeGlucagon‐like peptide‐1 (GLP‐1) is an important target for diabetes therapy based on its key role in maintaining glucose and lipid homeostasis. This study was designed to investigate antidiabetic and hepatoprotective effects of a novel oleanolic acid derivative DKS26 in diabetic mice and elucidate its underlying GLP‐1 related antidiabetic mechanisms in vitro and in vivo.Experimental ApproachThe therapeutic effects of DKS26 were investigated in streptozotocin (STZ)‐induced and db/db diabetic mouse models. Levels of plasma glucose, glycosylated serum protein (GSP), lipid profiles, insulin, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), oral glucose tolerance (OGT), pancreatic islets and hepatic histopathological morphology, liver lipid levels and expression of pro‐inflammatory cytokines were assessed. Intestinal NCI‐H716 cells and diabetic models were used to further validate its potential GLP‐1‐related antidiabetic mechanisms.Key ResultsDKS26 treatment (100 mg·kg−1·day−1 ) decreased plasma levels of glucose, GSP, ALT and AST; ameliorated OGT and plasma lipid profiles; augmented plasma insulin levels; alleviated islets and hepatic pathological morphology; and reduced liver lipid accumulation, inflammation and necrosis in vivo. Furthermore, DKS26 enhanced GLP‐1 release and expression, accompanied by elevated levels of cAMP and phosphorylated PKA in vitro and in vivo.Conclusion and ImplicationsDKS26 exerted hypoglycaemic, hypolipidaemic and islets protective effects, which were associated with an enhanced release and expression of GLP‐1 mediated by the activation of the cAMP/PKA signalling pathway, and alleviated hepatic damage by reducing liver lipid levels and inflammation. These findings firmly identified DKS26 as a new viable therapeutic option for diabetes control.

Oleanolic Acid Derivative NPLC441 Potently Stimulates Glucose Transport in 3T3-L1 Adipocytes Via a Multi-Target Mechanism

The Potential DPP-4 Inhibitors from Xiao-Ke-An Improve the Glucolipid Metabolism Via the Activation of AKT/GSK-3β Pathway.

Oleanolic Acid Derivative HA-20 Inhibits Adipogenesis in a Manner Involving PPARγ-FABP4/aP2 Pathway.

Synthesis and Evaluation of Novel Oleanolic Acid Derivatives As Potential Antidiabetic Agents

Oleanolic acid ameliorates high glucose-induced endothelial dysfunction via PPARδ activation

N-Oleoyl Glycine, a Lipoamino Acid, Stimulates Adipogenesis Associated with Activation of CB1 Receptor and Akt Signaling Pathway in 3T3-L1 Adipocyte

Structure Optimization of 12β-O-γ-Glutamyl Oleanolic Acid Derivatives Resulting in Potent FXR Antagonist/Modulator for NASH Therapy

Oleanolic Acid Reduces Hyperglycemia Beyond Treatment Period with Akt/FoxO1-Induced Suppression of Hepatic Gluconeogenesis in Type-2 Diabetic Mice

Antidiabetic Action of a Liver X Receptor Agonist Mediated By Inhibition of Hepatic Gluconeogenesis

Identification of a Novel Selective Agonist of PPARγ with No Promotion of Adipogenesis and Less Inhibition of Osteoblastogenesis

Synthesis and biological evaluation of oleanolic acid derivatives as PTP1B inhibitors.

A Novel Dual Peroxisome Proliferator-Activated Receptors Α and Γ Agonist with Beneficial Effects on Insulin Resistance and Lipid Metabolism

Synthesis and Biological Evaluation of Oleanolic Acid Derivatives As Inhibitors of Protein Tyrosine Phosphatase 1B.

Oleanolic Acid Derivative DKS26 Exerts Antidiabetic and Hepatoprotective Effects in Diabetic Mice and Promotes Glucagon‐like Peptide‐1 Secretion and Expression in Intestinal Cells

A new retinoid-like compound that activates peroxisome proliferator-activated receptors and lowers blood glucose in diabetic mice.

Design, synthesis, and biological evaluation of novel dual FFA1 and PPARδ agonists possessing phenoxyacetic acid scaffold

Antidiabetic potential of oleanolic acid from Ligustrum lucidum Ait.

Antidiabetic Potential of Oleanolic Acid from Ligustrum Lucidum Ait.This Article is One of a Selection of Papers Published in This Special Issue (part 2 of 2) on the Safety and Efficacy of Natural Health Products.

A Novel GPR120-selective Agonist Promotes Insulin Secretion and Improves Chronic Inflammation.

Insulin-sensitizing Effects of a Novel Α-Methyl-α-phenoxylpropionate Derivative in Vitro

Discovery of First-in-class Thiazole-Based Dual FFA1/PPARδ Agonists As Potential Anti-Diabetic Agents